Show simple item record

dc.contributor.authorPillay, Nisha
dc.contributor.authorBrady, Rosie M
dc.contributor.authorDey, Malini
dc.contributor.authorMorgan, Robert David
dc.contributor.authorTaylor, Stephen S
dc.date.accessioned2021-03-08T06:18:52Z
dc.date.available2021-03-08T06:18:52Z
dc.date.issued2021en
dc.identifier.citationPillay N, Brady RM, Dey M, Morgan RD, Taylor SS. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy. Prog Biophys Mol Biol. 2021.en
dc.identifier.pmid33524442en
dc.identifier.doi10.1016/j.pbiomolbio.2021.01.004en
dc.identifier.urihttp://hdl.handle.net/10541/623811
dc.description.abstractPoly (ADP-ribosyl)ation has central functions in maintaining genome stability, including facilitating DNA replication and repair. In cancer cells these processes are frequently disrupted, and thus interfering with poly (ADP-ribosyl)ation can exacerbate inherent genome instability and induce selective cytotoxicity. Indeed, inhibitors of poly (ADP-ribose) polymerase (PARP) are having a major clinical impact in treating women with BRCA-mutant ovarian cancer, based on a defect in homologous recombination. However, only around half of ovarian cancers harbour defects in homologous recombination, and most sensitive tumours eventually acquire PARP inhibitor resistance with treatment. Thus, there is a pressing need to develop alternative treatment strategies to target tumours with both inherent and acquired resistance to PARP inhibition. Several novel inhibitors of poly (ADP-ribose)glycohydrolase (PARG) have been described, with promising anti-cancer activity in vitro that is distinct from PARP inhibitors. Here we discuss, the role of poly (ADP-ribosyl)ation in genome stability, and the potential for PARG inhibitors as a complementary strategy to PARP inhibitors in the treatment of ovarian cancer.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.pbiomolbio.2021.01.004en
dc.titleDNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapyen
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKen
dc.identifier.journalProgress in Biophysics and Molecular Biologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record